Moteur de recherche d’entreprises européennes
Financement de l’UE (3 942 861 €) : Réseau de formation interdisciplinaire pour faire progresser la technologie des organes sur puce en Europe Hor12/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau de formation interdisciplinaire pour faire progresser la technologie des organes sur puce en Europe
EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emerging Organ-on-a-chip (OoC) technology. OoC technology is advancing at breath taking pace due to its potential impact in drug development and personalised treatments of disease. New researchers entering this field must be equipped with a multidisciplinary background ranging from biology to microfluidic chip engineering. EUROoC will offer the first complete and coherent European training program on OoC by gathering multidisciplinary participants (biologists, physicists, chemists, engineers) in a multi-sectoral network composed of 4 companies (3 SMEs), 2 regulation entities and 10 academic institutions. EUROoC will qualify the next generation of interdisciplinary scientists for all aspects of OoC development and utilisation, including understanding of commercialisation pathways and regulatory aspects. EUROoC furthermore comprises a collection of innovative research projects addressing the development of advanced OoC systems with higher physiological significance going beyond current in vitro testing. The EUROoC project will create advanced OoCs, which closely recapitulate properties of the respective organ tissues in vivo regarding cell types, microenvironment, organ-specific tissue structure and function as well as concepts for the interconnection of individual OoCs. The various OoC models to be developed comprise heart-on-a-chip, bone-on-a-chip, retina-on-a-chip, lung-on-a-chip, adipose- on-a-chip, gut-on-a-chip to liver-on-a-chip. The OoC systems will be able to monitor and analyse tissue functionality and response in situ by integrating various novel sensing elements. The OoCs developed will be pre-validated with the regulatory partners through in vitro-in vivo correlations. The research and training program planned will increase European competitiveness sustainably in this emerging key technology.
| Astrazeneca UK Ltd. | ? |
| Academisch Ziekenhuis Leiden | 531 240 € |
| Bundesinstitut Fuer Risikobewertung | 252 788 € |
| Ecole Polytechnique Federale DE Lausanne | 281 277 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 323 007 € |
| Miltenyi Biotec B.V. & Co. KG | 224 701 € |
| Miltenyi Biotec GmbH | 28 088 € |
| Naturwissenschaftliches UND Medizinisches Institut AN DER Universitaet Tuebingen | 182 569 € |
| Technische Universitaet Graz | 528 414 € |
| Universitaet Bern | 281 277 € |
| Universitatsklinikum Jena | 505 577 € |
| Universite Du Luxembourg | 256 320 € |
| Universiteit Twente | 265 620 € |
| Uppsala Universitet | 281 983 € |
https://cordis.europa.eu/project/id/812954
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Astrazeneca UK Ltd., Cambridge, Royaume Uni.
